MARÍA
GÓMEZ CAÑAS
Profesora ayudante doctora
Instituto Ramón y Cajal de Investigación Sanitaria
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto Ramón y Cajal de Investigación Sanitaria (25)
2023
-
Endocannabinoid-Binding Receptors as Drug Targets
Methods in molecular biology (Clifton, N.J.), Vol. 2576, pp. 67-94
2022
-
Editorial: Cannabinoids as potential treatment for neurological diseases
Frontiers in Neuroscience
2021
-
Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease
European Journal of Pharmacology, Vol. 895
-
Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease
Molecules, Vol. 26, Núm. 11
-
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Molecular and Cellular Neuroscience, Vol. 110
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
2020
-
Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors
British Journal of Pharmacology, Vol. 177, Núm. 17, pp. 4034-4054
2019
-
Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease
Molecules, Vol. 24, Núm. 15
-
Structure–effect relationships of novel semi-synthetic cannabinoid derivatives
Frontiers in Pharmacology, Vol. 10
2018
-
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor
Journal of Neuroinflammation, Vol. 15, Núm. 1
-
Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists
Bioorganic and Medicinal Chemistry, Vol. 26, Núm. 1, pp. 295-307
-
VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways
British Journal of Pharmacology, Vol. 175, Núm. 19, pp. 3813-3831
2017
-
Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)
Pharmacological Research
-
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking
European Journal of Medicinal Chemistry, Vol. 127, pp. 398-412
2016
-
Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile
Pharmacological Research, Vol. 110, pp. 205-215
-
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis
Journal of Medicinal Chemistry, Vol. 59, Núm. 14, pp. 6753-6771
-
Exploring the Benzimidazole Ring as a Substitution for Indole in Cannabinoid Allosteric Modulators
Cannabis and Cannabinoid Research, Vol. 1, Núm. 1, pp. 196-201
-
Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology
Journal of Medicinal Chemistry, Vol. 59, Núm. 5, pp. 1840-1853
-
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways
Scientific Reports, Vol. 6
-
Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2receptor ligands with antagonist/inverse agonist properties
European Journal of Medicinal Chemistry, Vol. 112, pp. 66-80